PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN

Data demonstrate the drug candidate's potential to become the first phosphate binder to increase iron stores while reducing the need for IV iron and erythropoiesis-stimulating agents in end-stage renal disease patients on dialysis

2014-07-25
(Press-News.org) New York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication of results from the long-term, randomized, active control Phase 3 study of Zerenex (ferric citrate), the Company's investigational oral ferric iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis. The PERFECTED study (PhosphatE binding and iRon delivery with FErric CiTrate in EsrD) was published online today in the Journal of the American Society of Nephrology (JASN).

This Phase 3 study was a multicenter, randomized, open-label trial in 441 ESRD patients on hemodialysis or peritoneal dialysis designed to determine the safety and efficacy of Zerenex as a treatment to reduce serum phosphorus as well as raise iron stores and reduce intravenous (IV) iron and erythropoietin-stimulating agents (ESA) usage.

Zerenex met the study's primary end-point demonstrating a highly statistically significant change in serum phosphorus versus placebo over the four-week Placebo Control Period. Using a sequential gatekeeping strategy for the key pre-defined secondary end-points, Zerenex also demonstrated statistically significant increases in serum ferritin and transferrin saturation (TSAT), and significant reductions in the use of IV iron and ESAs, versus an active control of Renvela® (sevelamer carbonate) and/or Phoslo® (calcium acetate) over the 52-week Active Control Period of the study. In addition, mean hemoglobin levels were higher in subjects treated with Zerenex as compared to subjects treated with active control.

"Zerenex effectively reduces serum phosphorus levels within the KDOQI range (3.5 mg/dL to 5.5 mg/dL) while having the additional patient benefits of increasing iron stores and decreasing the need for IV iron and ESAs, while maintaining hemoglobin levels," said Julia Lewis, MD, lead investigator, nephrologist and Professor of Medicine at Vanderbilt University Medical Center. "If approved, the combined benefits of Zerenex would be of value for patients, health care professionals and the healthcare system."

The Company's New Drug Application (NDA) for Zerenex is currently under review by the U.S. Food and Drug Administration (FDA).

Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are very pleased with the publication of the Phase 3 PERFECTED study results in a premier peer-reviewed nephrology journal and are encouraged by Zerenex's potential differentiated product profile." Mr. Bentsur added, "We thank the investigators and patients who participated in this study and look forward to potentially bringing Zerenex to market in the U.S."

Phosphorus Control is Necessary for Most ESRD Patients on Dialysis

In the United States, according to data from the U.S. Renal Data System, there are currently approximately 600,000 ESRD patients, with the number of ESRD patients projected to rise in the future. The majority of ESRD patients in the United States, more than 400,000, require dialysis. Phosphate retention and the resulting hyperphosphatemia in patients with ESRD on dialysis are associated with secondary hyperparathyroidism, renal osteodystrophy, soft tissue mineralization and an increase in adverse cardiovascular events. Hyperphosphatemia is ubiquitous in ESRD, with the majority of the patients requiring chronic treatment with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels.

Zerenex Administration Over 52 Weeks Increased Iron Stores

In addition, approximately seventy percent of dialysis patients are truly or functionally iron depleted, suffer from anemia and require treatment with IV iron and/or ESA injections. The newly published clinical trial results show that, in addition to its efficacy as a phosphate binder, Zerenex also significantly raises iron stores as measured by serum ferritin and TSAT.

The results showed Zerenex demonstrated a statistically significant treatment difference versus the active control group in mean change in serum ferritin (+306 ng/mL vs. +19 ng/mL) and TSAT (+8% vs -1.2%) from baseline (day 0) to week 52. In the PERFECTED study, subjects randomized to receive Zerenex required significantly lower dosages of IV iron and ESA; and hemoglobin levels were higher in Zerenex treated patients than in those receiving active control.

The investigators cited an analysis of the trial results that indicated that the projected reduction in the need for IV iron and ESA use would result in significant pharmaco-economic benefits. In addition, the investigators wrote, "one would postulate that decreased IV iron and ESA usage could result in decreased nursing time to administer IV medications which could be redirected to other aspects of patient care and decreased risk of infections due to fewer IV injections." In the PERFECTED study, fewer serious adverse events (SAEs) due to infection were seen in the subjects randomized to Zerenex compared to active control.

The authors noted that, if approved, Zerenex would be the only phosphate binder that also increases iron stores and decreases IV iron and ESA use.

Study Design and Results

Subjects in the PERFECTED study (n=441) first entered a 2-week washout period and were then randomized in a 2:1 ratio to receive either Zerenex or an active control of Renvela® (sevelamer carbonate) and/or Phoslo® (calcium acetate) for a 52-week Active Control Period. This was then followed by a 4-week Placebo Control Period in which Zerenex subjects were again randomized to either continue on Zerenex or switch to placebo. Zerenex was administered as 1 gram tablets each containing 210 mg of ferric iron. Active control study drugs were administered as calcium acetate 667 mg capsules, sevelamer carbonate 800 mg tablets alone or in combination.

The primary end-point of this trial was the mean change in serum phosphorus from baseline (Week 52) to the end of the 4-week Placebo Control Period. A prospectively designed sequential gatekeeping strategy controlled study-wise type 1 error for serum ferritin, TSAT, IV iron and ESA usage as pre-specified secondary endpoints in the 52-week Active Control Period.

The primary end-point demonstrated mean serum phosphorus was lower in the ferric citrate group versus the placebo group with a mean treatment difference of -2.2 ± 0.2 mg/dL (P END


ELSE PRESS RELEASES FROM THIS DATE:

New research suggests Saharan dust is key to the formation of Bahamas' Great Bank

New research suggests Saharan dust is key to the formation of Bahamas Great Bank
2014-07-25
MIAMI – A new study suggests that Saharan dust played a major role in the formation of the Bahamas islands. Researchers from the University of Miami (UM) Rosenstiel School of Marine and Atmospheric Science showed that iron-rich Saharan dust provides the nutrients necessary for specialized bacteria to produce the island chain's carbonate-based foundation. UM Rosenstiel School Lewis G. Weeks Professor Peter Swart and colleagues analyzed the concentrations of two trace elements characteristic of atmospheric dust – iron and manganese – in 270 seafloor samples collected along ...

Overweight and obese preschoolers lose more weight when parent is also treated

Overweight and obese preschoolers lose more weight when parent is also treated
2014-07-24
BUFFALO, N.Y. – Primary care treatment of overweight and obese preschoolers works better when treatment targets both parent and child compared to when only the child is targeted, according to research published this week in Pediatrics and conducted at the University at Buffalo and Women and Children's Hospital of Buffalo. Children enrolled in this study were overweight or obese and had one parent who participated in the study who also was overweight or obese, according to body mass index (BMI) measurements, calculated based on height and weight. During the course of the ...

NYSCF scientists one step closer to cell therapy for multiple sclerosis patients

2014-07-24
NEW YORK, NY (July 24, 2014) – Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient's own cells. For the first time, NYSCF scientists generated induced pluripotent stem (iPS) cells lines from skin samples of patients with primary progressive multiple sclerosis and further, they developed an accelerated protocol to induce these stem cells into becoming oligodendrocytes, the myelin-forming cells of the central nervous system implicated in multiple ...

Study indicates large raptors in Africa used for bushmeat

2014-07-24
Bushmeat, the use of native animal species for food or commercial food sale, has been heavily documented to be a significant factor in the decline of many species of primates and other mammals. However, a new study indicates that more than half of the species being consumed are birds, particularly large birds like raptors and hornbills. "By surveying not only the meat made available for sale but the meat that is being eaten inside the forest by hunters and brought to villages for consumption, we noted a significant percentage attributed to bird species," said Bethan ...

New study draws links between wildlife loss and social conflicts

2014-07-24
Citing many sobering examples of how wildlife loss leads to conflict among people around the world, a new article co-authored by Wildlife Conservation Society (WCS) Health & Ecosystems: Analysis of Linkages (HEAL) Program Director Dr. Christopher Golden, calls for an interdisciplinary approach to tackle global biodiversity decline. The harvest of wild animals directly supports about 15% of the world's people and provides protein for more than a billion of the world's poor. It should come as no surprise that today's unprecedented loss of wildlife, is bringing with it ...

Hubble finds 3 surprisingly dry exoplanets

Hubble finds 3 surprisingly dry exoplanets
2014-07-24
Astronomers using NASA's Hubble Space Telescope have gone looking for water vapor in the atmospheres of three planets orbiting stars similar to the sun -- and have come up nearly dry. The three planets, known as HD 189733b, HD 209458b, and WASP-12b, are between 60 and 900 light-years away from Earth and were thought to be ideal candidates for detecting water vapor in their atmospheres because of their high temperatures where water turns into a measurable vapor. These so-called "hot Jupiters" are so close to their star they have temperatures between 1,500 and 4,000 degrees ...

The microbes make the sake brewery

2014-07-24
A sake brewery has its own microbial terroir, meaning the microbial populations found on surfaces in the facility resemble those found in the product, creating the final flavor according to research published ahead of print in the journal Applied and Environmental Microbiology. This is the first time investigators have taken a microbial census of a sake brewery. Many sake makers inoculate with both bacteria and yeast, says corresponding author David A. Mills of the University of California, Davis, but he and his colleagues investigated a sake brewery where inoculation ...

New imaging agent provides better picture of the gut

2014-07-24
MADISON — A multi-institutional team of researchers has developed a new nanoscale agent for imaging the gastrointestinal (GI) tract. This safe, noninvasive method for assessing the function and properties of the GI tract in real time could lead to better diagnosis and treatment of gut diseases. Illnesses such as small bowel bacterial overgrowth, irritable bowel syndrome and inflammatory bowel disease all occur in the intestine and can lead to serious side effects in patients with diseases such as diabetes and Parkinson's. Until now, there hasn't been a good way to ...

Brain's dynamic duel underlies win-win choices

Brains dynamic duel underlies win-win choices
2014-07-24
People choosing between two or more equally positive outcomes experience paradoxical feelings of pleasure and anxiety, feelings associated with activity in different regions of the brain, according to research led by Amitai Shenhav, an associate research scholar at the Princeton Neuroscience Institute at Princeton University. In one experiment, 42 people rated the desirability of more than 300 products using an auction-like procedure. Then they looked at images of paired products with different or similar values and were asked to choose between them. Their brain activity ...

TGen-led study seeks to understand why some HIV-positive men are more infectious

TGen-led study seeks to understand why some HIV-positive men are more infectious
2014-07-24
FLAGSTAFF, Ariz. — July 24, 2014 — A new study led by the Translational Genomics Research Institute (TGen) provides insights into the interplay among bacteria, viruses and the immune system during HIV infection. Currently, doctors measure HIV-positive men's infectivity — their potential to infect others — based on their blood viral load. However, some men produce large amounts of virus in their semen despite having low levels in their blood. Researchers call this "compartmentalization," where different levels of the virus can be found in different parts of the body; in ...

LAST 30 PRESS RELEASES:

Researchers improve chemical reaction that underpins products from foods to fuels

Texas Tech to develop semiconductor power devices through $6 million grant

Novel genomic screening tool enables precision reverse-engineering of genetic programming in cells

Hot Schrödinger cat states created

How cells repair their power plants

Oxygen is running low in inland waters—and humans are to blame

ACP’s Best Practice Advice addresses use of cannabis, cannabinoids for chronic noncancer pain

Beyond photorespiration: A systematic approach to unlocking enhanced plant productivity

How a small number of mutations can fuel outbreaks of western equine encephalitis virus

Exposure to wildfire smoke linked with worsening mental health conditions

Research uncovers hidden spread of one of the most common hospital-associated infections

Many older adults send their doctors portal messages, but who pays?

Fine particulate matter from 2020 California wildfires and mental health–related emergency department visits

Gender inequity in institutional leadership roles in US academic medical centers

Pancreatic cells ‘remember’ epigenetic precancerous marks without genetic sequence mutations

Rare combination of ovarian tumors found in one patient

AI-driven clinical recommendations may aid physician decision making to improve quality of care

Artificial intelligence has potential to aid physician decisions during virtual urgent care

ACP and Annals of Internal Medicine present breaking scientific news at ACP’s Internal Medicine Meeting 2025

New study reveals polymers with flawed fillers boost heat transfer in plastics

Signs identified that precede sudden arrhythmic death syndrome in young people

Discovery of bacteria's defence against viruses becomes a piece of the puzzle against resistance

Pre-eclampsia is associated with earlier onset and higher incidence of cardiovascular risk factors

Warwick astronomers discover doomed pair of spiralling stars on our cosmic doorstep

Soil conditions significantly increase rainfall in world’s megastorm hotspots

NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma

Planetary health diet and mediterranean diet associated with similar survival and sustainability benefits

Singapore launches national standard to validate antimicrobial disinfectant products

Molecular stool test could improve detection of tuberculosis in adults with HIV

Suspected fibrocartilaginous embolus in Asian small-clawed otter (Aonyx cinereus)

[Press-News.org] Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN
Data demonstrate the drug candidate's potential to become the first phosphate binder to increase iron stores while reducing the need for IV iron and erythropoiesis-stimulating agents in end-stage renal disease patients on dialysis